August 2012
-
Adherium has announced that Helicon Health, a spin out from the UCL Centre for Health Informatics and Multi Professional Education, will market Adherium’s Hailie inhaler sensors and monitoring service in the UK. According to the… Read more . . .
-
Oragenics has published data from studies of its NT-CoV-2-1 proteosome adjuvanted intranasal vaccine candidate against SARS-CoV-2 in mice and hamsters that support further development of the vaccine, the company said. The data were published June… Read more . . .
-
Optinose has announced that the Phase 3 ReOpen2 trial of Xhance fluticasone propionate nasal spray (OPN-375) in patients with chronic sinusitis without nasal polyps demonstrated significant improvement compared to placebo in both patient reported symptoms at… Read more . . .
-
Posted on OINDPnews on June 9, 2022Company: ModernaLocation: Norwood, MA, USA The Role:This role is an exciting opportunity to be a critical part of a team enabling respiratory delivery of mRNA at an organization that is radically… Read more . . .
-
According to CounterAct, the Canadian Intellectual Property Office has issued a patent (3065307, “Prescription bottle cap capable of administering opioid overdose reversal agent”) covering the company’s naloxone nasal spray cap. CounterAct co-founder Todd Pizitz commented, “We are pleased… Read more . . .
-
Opiant Pharmaceuticals announced that it has signed an agreement with Aptar Pharma for expanded production of Aptar’s Unidose device in order to support potential commercial demand for Opiant’s OPNT003 intranasal nalmefene. The agreement includes €2… Read more . . .
-
Tiziana Life Sciences has announced that a second multiple sclerosis patient who received the company’s intranasal foralumab for three months as part of an expanded access program at Brigham and Women’s Hospital (BWH) has showed… Read more . . .
-
Device company RxPack has joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) as an associate member, the company said. RxPack is a joint venture between Lindal Group and Coster Group that was formed… Read more . . .
-
Following an advice meeting with the Paul Erhlich Institute, Israeli biopharm company BiondVax Pharmaceuticals announced plans for development of its lead candidate, an inhaled COVID-19 nanosized antibody (NanoAb) therapy. The company said that it hopes… Read more . . .
-
Opiant Pharmaceuticals said that it has filed the first part of a 505(b)(2) NDA for OPNT003 intranasal nalmefene for the treatment of opioid overdose and that it expects to complete the submission later this year.… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.